Therapeutic Effects of Melatonin Receptor Agonists on Sleep and Comorbid Disorders
Year: 2014
Type: review
Abstract: Several melatonin receptors agonists (ramelteon, prolonged-release melatonin, agomelatine and tasimelteon) have recently become available for the treatment of insomnia, depression and circadian rhythms sleep-wake disorders. The efficacy and safety profiles of these compounds in the treatment of the indicated disorders are reviewed. Accumulating evidence indicates that sleep-wake disorders and co-existing medical conditions are mutually exacerbating. This understanding has now been incorporated into the new Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5). Therefore, when evaluating the risk/benefit ratio of sleep drugs, it is pertinent to also evaluate their effects on wake and comorbid condition. Beneficial effects of melatonin receptor agonists on comorbid neurological, psychiatric, cardiovascular and metabolic symptomatology beyond sleep regulation are also described. The review underlines the beneficial value of enhancing physiological sleep in comorbid conditions.
Authors: Moshe Laudon, Anat Frydman-Marom
Institution: Neurim Pharmaceuticals (Israel)
Language: English
Subfield: Endocrine and Autonomic Systems
Field: Neuroscience
Domain: Life Sciences
Keywords: melatonin receptor agonists, ramelteon, prolonged-release melatonin, agomelatine, tasimelteon, insomnia, depression, circadian rhythm disruption, comorbidities, sleep-wake disorders, risk-benefit assessment, cardiovascular effects, metabolic effects, neurological effects, psychiatric effects
Open Access status: gold
Estimated APC paid: $3,499
OpenAlex ID: W2158639142
